williams glp 1 Serena Opens Up About Being on a GLP-1 Serena Williams weight loss drug:

1 (1999): 924, 10.1016/S0167-0115(99)00089-0

Much of what we know comes from animal studies

Albiglutide Albiglutide achieves extended systemic activity through genetic fusion with human serum albumin (HSA), a strategy distinct from the fatty acid-based albumin binding used in agents like liraglutide and semaglutide

Supports weight management while protecting lean mass Along with the lean mass increase mentioned in the study above, using 1-2 Glucerna servings as partial meal replacements over 90 days also led 2 x greater weight loss of visceral adipose tissue (belly fat) +8 3

The safety and glycaemic efficacy of tirzepatide as an additional treatment for Japanese subjects with T2D who were not achieving adequate glycemic control with various oral antihyperglycaemic monotherapies (SURPASS-J combo trial) were similar to those observed in the SURPASS-J mono trial [141]

BC: Funding acquisition, Supervision, Writingreview and editing